Home
|
Contact us
|
Disclaimer
Corporate Overview
Management
Board of Directors
Business Ethics
Contact us
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
Current partnership
In/Out-licensing opportunity
ELND005 Phase II
Stock quote
Financial reports
Analyst coverage
Request information
Subscribe to e-mail alert
Press release 2011
Press release archive
Webcast and presentation
SCIENCE & technologies
Product pipeline
ELND005
Anti-inflammation
Anti-diabetes compounds
ALZHEIMER'S DISEASE
TYPE 2 DIABETES / OBESITY
ARTHRITIS
* Phase III ready
© 2011 Transition Therapeutics Inc.